COVID-19-associated orthostatic hypotension syndrome: direct and indirect mechanisms of development

Abstract

Background. The article presents an observation of the clinical case of orthostatic hypotension that developed after an infection caused by the SARS-CoV-2 virus. The issues of etiology, pathogenesis, diagnosis are outlined. The complexity of diagnosis at the stage of clinical observation is due to the comorbidity of possible mechanisms and the difficulty of determining the primary factor. Taking into account the study of variants of direct and indirect action of this 2019-nCoV, the description of the clinical observation of orthostatic hypotension supplements the data on the spectrum of manifestations of this disease.

Aim.  Analysis of the clinical case of the development of orthostatic hypotension in the post-acute period of COVID-19.

Material. When conducting a literature review on the selected topic, various sources were considered. The search depth was over 7 years. For the recruitment of literature, Internet platforms UpToDate, PubMed, Medscape were used. Russian and foreign sources were studied.

Methods. Anamnesis collection, objective research, specialized tests, laboratory and instrumental research methods, study of disease history, literature sources on orthostatic hypotension and the effect of COVID-19 on the autonomic nervous system.

Results. The analysis of this case with the determination of the leading mechanism of orthostatic hypotension is extremely difficult. Probably, there is a combination of factors: direct and indirect effects on the nervous system at COVID-19. The direct effect is associated with the interaction of the virus with the angiotensin converting enzyme 2 receptors in the nervous system, which causes a significant increase in the concentration of bradykinin and the development of hypotension. An indirect effect is due to both increased thrombus formation with the development of PE, and autonomic dysfunction, within the framework of secondary polyneuropathy of fine fibers.

Conclusion. It is likely that in the near future the number of such patients in the practice of doctors will increase, therefore, timely and correct diagnosis of these conditions, with their careful management, will be the fundamental postulates in the recovery of patients. Drawing attention to this topic will possibly expand our understanding of the spectrum of complications of COVID-19 and will greatly complement the information available today.

Keywords

orthostatic hypotension / COVID-19 complications / COVID-19 / autonomic nervous system

References

[1] Palma J.A., Kaufmann H. Management of orthostatic hypotension. Continuum (Minneap. Minn.). 2020; 26 (1): 154–177. DOI: 10.1212/CON.0000000000000816.

[2] Palma J.A., Kaufmann H. Management of orthostatic hypotension // Continuum (Minneap. Minn.). 2020. Vol. 26, N. 1. P. 154–177. DOI: 10.1212/CON.0000000000000816.

[3] Ricci F., De Caterina R., Fedorowski A. Orthostatic hypotension: Epidemiology, prognosis, and treatment. J. Am. Coll. Cardiol. 2015; 66 (7): 848–860. DOI: 10.1016/j.jacc.2015.06.1084.

[4] Ricci F., De Caterina R., Fedorowski A. Orthostatic hypotension: Epidemiology, prognosis, and treatment // J. Am. Coll. Cardiol. 2015. Vol. 66, N. 7. P. 848–860. DOI: 10.1016/j.jacc.2015.06.1084.

[5] Kanjwal K., George A., Figueredo V.M. et al. Orthostatic hypotension: definition, diagnosis and management. J. Cardiovasc. Med. (Hagerstown). 2015; 16 (2): 75–81. DOI: 10.2459/01 JCM.0000446386.01 100.3.

[6] Kanjwal K., George A., Figueredo V.M. et al. Orthostatic hypotension: definition, diagnosis and management // J. Cardiovasc. Med. (Hagerstown). 2015. Vol. 16, N. 2. P. 75–81. DOI: 10.2459/01 JCM.0000446386.01 100.3.

[7] Tzur I., Izhakian S., Gorelik O. Orthostatic hypotension: definition, classification and evaluation. Blood Pressure. 2019; 28 (3): 146–156. DOI: 10.1080/08037051.2019.1604067.

[8] Tzur I., Izhakian S., Gorelik O. Orthostatic hypotension: definition, classification and evaluation // Blood Pressure. 2019. Vol. 28, N. 3. P. 146–156. DOI: 10.1080/08037051.2019.1604067.

[9] Ostroumova O.D., Cherniaeva M.S., Petrova M.M., Golovina O.V. Orthostatic hypotension: Definition, pathophysiology, classification, prognostic aspects, diagnostics and treatment. Rational Pharmacotherapy in Cardiology. 2018; 14 (5): 747–756. DOI: 10.20996/1819-6446-2018-14-5-747-756. (In Russ.)

[10] Остроумова О.Д., Черняева М.С., Петрова М.М., Головина О.В. Ортостатическая гипотензия: определение, патофизиология, классификация, прогностические аспекты, диагностика и лечение // Рационал. фармакотерап. в кардиол. 2018. Т. 14, №5. С. 747–756. DOI: 10.20996/1819-6446-2018-14-5-747-756.

[11] Freeman R., Wieling W., Axelrod F.B. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 2013; 21 (2): 69–72. DOI: 10.1007/s10286-011-0119-5.

[12] Freeman R., Wieling W., Axelrod F.B. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome // Clin. Auton. Res. 2013. Vol. 21, N. 2. P. 69–72. DOI: 10.1007/s10286-011-0119-5.

[13] Gibbons C.H., Freeman R. Delayed orthostatic hypotension. Auton. Neurosci. 2020; 229: 102724. DOI: 10.1016/j.autneu.2020.102724.

[14] Gibbons C.H., Freeman R. Delayed orthostatic hypotension // Auton. Neurosci. 2020. Vol. 229. P. 102724. DOI: 10.1016/j.autneu.2020.102724.

[15] Brignole M., Moya A., de Lange F.J. et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur. Heart J. 2018; 39 (21): 1883–1948. DOI: 10.1093/eurheartj/ehy037.

[16] Brignole M., Moya A., de Lange F.J. et al. 2018 ESC Guidelines for the diagnosis and management of syncope // Eur. Heart J. 2018. Vol. 39, N. 21. P. 1883–1948. DOI: 10.1093/eurheartj/ehy037.

[17] Freeman R., Abuzinadah A.R., Gibbons C. et al. Orthostatic hypotension: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2018; 72 (11): 1294–1309. DOI: 10.1016/j.jacc.2018.05.079.

[18] Freeman R., Abuzinadah A.R., Gibbons C. et al. Orthostatic hypotension: JACC state-of-the-art review // J. Am. Coll. Cardiol. 2018. Vol. 72, N. 11. P. 1294–1309. DOI: 10.1016/j.jacc.2018.05.079.

[19] Yamamoto V., Bolanos J.F., Fiallos J. et al. COVID-19: Review of a 21st century pandemic from etiology to neuro-psychiatric implications. J. Alzheimer’s Dis. 2020; 77 (2): 459–504. DOI: 10.3233/JAD-200831.

[20] Yamamoto V., Bolanos J.F., Fiallos J. et al. COVID-19: Review of a 21st century pandemic from etiology to neuro-psychiatric implications // J. Alzheimer’s Dis. 2020. Vol. 77, N. 2. P. 459–504. DOI: 10.3233/JAD-200831.

[21] Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin. Med. (Lond.). 2021; 21 (1): e63-e67. DOI: 10.7861/clinmed.2020-0896.

[22] Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies // Clin. Med. (Lond.). 2021. Vol. 21, N. 1. P. e63–e67. DOI: 10.7861/clinmed.2020-0896.

[23] Konig M.F., Powell M., Staedtke V. et al. Preventing cytokine storm syndrome in COVID-19 using α-adrenergic receptor anta-gonists. J. Clin. Invest. 2020; 130 (7): 3345–3347. DOI: 10.1172/JCI139642.

[24] Konig M.F., Powell M., Staedtke V. et al. Preventing cytokine storm syndrome in COVID-19 using α-adrenergic receptor antagonists // J. Clin. Invest. 2020. Vol. 130, N. 7. P. 3345–3347. DOI: 10.1172/JCI139642.

[25] Staedtke V., Bai R.Y., Kim K. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018; 564 (7735): 273–277. DOI: 10.1038/s41586-018-0774-y.

[26] Staedtke V., Bai R.Y., Kim K. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome // Nature. 2018. Vol. 564, N. 7735. P. 273–277. DOI: 10.1038/s41586-018-0774-y.

[27] Zubair A.S., McAlpine L.S., Gardin T. et al. Neuropathoge-nesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019. JAMA Neurol. 2019; 77 (8): 1018. DOI: 10.1001/jamaneurol.2020.2065.

[28] Zubair A.S., McAlpine L.S., Gardin T. et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease // JAMA Neurol. 2019. Vol. 77, N. 8. P. 1018. DOI: 10.1001/jamaneurol.2020.2065.

[29] Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. eNeurological. Sci. 2020; 21: 100276. DOI: 10.1016/j.ensci.2020.100276.

[30] Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report // eNeurological. Sci. 2020. Vol. 21. P. 100276. DOI: 10.1016/j.ensci.2020.100276.

[31] Dalakas M.C. Guillain–Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflamm. 2020; 7 (5): e781. DOI: 10.1212/NXI.0000000000000781.

[32] Dalakas M.C. Guillain–Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing // Neurol. Neuroimmunol. Neuroinflamm. 2020. Vol. 7, N. 5. P. e781. DOI: 10.1212/NXI.0000000000000781.

[33] Prandoni P., Anthonie W.A., Martin H. et al. Prevalence of pulmonary embolism among patients hospitalized for syncope. N. Engl. J. Med. 2016; 375: 1524. DOI: 10.1056/NEJMoa1602172.

[34] Prandoni P., Anthonie W.A., Martin H. et al. Prevalence of pulmonary embolism among patients hospitalized for syncope // N. Engl. J. Med. 2016. Vol. 375. P. 1524. DOI: 10.1056/NEJMoa1602172.

[35] Runser L.A., Gauer R.L., Houser A. Syncope: Evaluation and differential diagnosis. Am. Family Physician. 2017; 95 (5): 303–312. PMID: 28290647.

[36] Runser L.A., Gauer R.L., Houser A. Syncope: Evaluation and differential diagnosis // Am. Family Physician. 2017. Vol. 95, N. 5. P. 303–312. PMID: 28290647.

[37] Agashe S., Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc. J. 2018; 14 (4): 251–256. DOI: 10.14797/mdcj-14-4-251.

[38] Agashe S., Petak S. Cardiac autonomic neuropathy in diabetes mellitus // Methodist Debakey Cardiovasc. J. 2018. Vol. 14, N. 4. P. 251–256. DOI: 10.14797/mdcj-14-4-251.

[39] Milovanovic B., Djajic V., Bajic D. et al. Assessment of autonomic nervous system dysfunction in the early phase of infection with SARS-CoV-2 virus. Front. Neurosci. 2021; 15: 1–14.

[40] Milovanovic B., Djajic V., Bajic D. et al. Assessment of autonomic nervous system dysfunction in the early phase of infection with SARS-CoV-2 virus // Front. Neurosci. 2021. Vol. 15. P. 1–14.

[41] Serhiyenko V.A., Serhiyenko A.A. Cardiac autonomic neuro-pathy: Risk factors, diagnosis and treatment. World J. Diabetes. 2018; 9 (1): 1–24. DOI: 10.4239/wjd.v9.i1.1.

[42] Serhiyenko V.A., Serhiyenko A.A. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment // World J. Dia-betes. 2018. Vol. 9, N. 1. P. 1–24. DOI: 10.4239/wjd.v9.i1.1.

[43] Bissinger A. Cardiac autonomic neuropathy: Why should cardiologists care about that? J. Diabetes Res. 2017; 2017: 5374176. DOI: 10.1155/2017/5374176.

[44] Bissinger A. Cardiac autonomic neuropathy: Why should cardiologists care about that? // J. Diabetes Res. 2017. Vol. 2017. P. 5374176. DOI: 10.1155/2017/5374176.

RIGHTS & PERMISSIONS

Mendelevich E.G., Saifeeva A.A., Kurbanov A.I.